It was another fine morning for Paige, the New York-based, next-generation Artificial Intelligence (AI) cancer company.
On Thursday the company debuted Paige Alba, a clinical-grade multimodal co-pilot designed to revolutionize personalized medicine and precision oncology.
Among all the cancer-focused companies that have hitched their wagon to AI, Paige is an undeniable leader in this space.
Paige Alba allows pathologists to access comprehensive, patient-specific summaries—including prior pathology reports, radiology findings, and patient history—within seconds.
This reduces time spent on administrative tasks and enables to make faster, more informed decisions. Truly interactive, Alba can order stains or complete a report, all through voice commands, which can help facilitate routine workflow tasks.
In an exclusive interview with BreakingCancerNews.com, Dr. Juan Retamero, Medical Vice President, Pathology Operations for Diagnostic Products at Paige, described the technology.
“Paige Alba has the future potential to transform patient care by providing clinicians with deeper, faster insights that lead to more informed decisions,” he explained.
“By integrating clinical and patient history, radiological, pathological, and molecular data, Alba can empower healthcare teams to deliver more personalized diagnoses and precise treatments, ultimately improving outcomes for patients.”
The execs at Paige described today how this technology pushes the boundaries of cancer diagnostics and precision oncology–and technologically, how Paige is building its AI to deliver Artificial General Intelligence (AGI) for cancer diagnostics.
Using the power of Paige’s Foundation Models, Alba delivers AI-driven patient insights in real-time and marks a significant step toward Artificial General Intelligence (AGI).
Alba seamlessly integrates state-of-the-art computational pathology large vision models (LVMs) with conversational large language models (LLMs).
Bringing together multiple AI-driven insights into a single, cohesive solution provides a unique, real-time interactive experience for pathologists, oncologists, multidisciplinary clinical teams and in clinical trials management.
A significant feature of Alba is its ability to aggregate and summarize patient data from the multiple data sources that exist in hospitals, including Electronic Health Records (EHRs), Laboratory Information Systems (LIS), and Image Management Systems (IMS), which are readily available nationwide.
By eliminating the need to navigate multiple platforms, Alba’s experts say that it allows pathologists to access comprehensive, patient-specific summaries—including prior pathology reports, radiology findings, and patient history—within seconds.
This reduces time spent on administrative tasks and enables faster, more informed decision-making.
“Pathologists often struggle with the lack of clinical context essential for reaching a precise diagnosis,” said Retamero in a press statement.
“Alba’s natural language processing capabilities, combined with its integration with other clinical software solutions, provide this critical context, facilitating multidisciplinary collaboration and resolving discrepancies between radiology and pathology. In addition, Alba acts as a digital assistant that can order stains or complete a report, all through voice commands, which can help facilitate routine workflow tasks”.
Alba leverages Paige’s portfolio of clinical-grade AI to analyze all the digital images associated with a case, highlighting areas suspicious for cancer and providing interim case evaluations for expert review.
This includes Paige Omniscreen™, which uses AI to screen multiple molecular biomarkers from tissue.
By integrating clinical, pathological, and biomarker data, Alba consolidates relevant information, supports physicians in providing diagnostic recommendations, and automatically generates pathology reports.
These reports can then be reviewed, modified, supplemented, and approved by the pathologist using voice commands, enhancing the overall efficiency of the diagnostic process.
“Integrating multiple AI technologies and capabilities into a single system in this way has the potential to support complex decision making in cancer patients. In the same way that even the best airline pilots rely on co-pilots to gather data and guide decision-making, Alba ensures that clinicians are supported and guided with the most relevant, timely, and comprehensive information,” Razik Yousfi, CTO and CEO of Paige, said in a press statement.
“With Alba, we are not just enhancing diagnostic precision—we are empowering clinicians with a truly intelligent and interactive co-pilot.”
The company notes that Paige Alba™ is for research use only (RUO), not for use in diagnostic procedures.
